Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
To explore the effectiveness and safety of Camrelizumab based cross-line therapy for patients with advanced NSCLC in the real world
NSCLC
DRUG: Camrelizumab
Objective Response Rate (ORR) in second-line treatment of patients with non-small cell lung cancer based on Camrelizumab regimen, CR+PR, Up to 12 months
Evaluation of Progression Free survival (PFS) in patients with non-small cell lung cancer based on first-line/second-line treatment with Camrelizumab, Progression free survival (PFS) according to RECIST 1.1, Up to 36 months|Evaluation of second progression-free survival (PFS2) in patients with non-small cell lung cancer based on Camrelizumab regimen, Evaluation of second progression-free survival (PFS2) in patients with non-small cell lung cancer based on Camrelizumab regimen, Up to 12 months|OS, Overall survival, Up to 12 months|To evaluate the safety of Camrelizumab based first/second line therapy in patients with non-small cell lung cancer, according to NCI-CTCAE version 5.0, Up to 12 months
To explore the effectiveness and safety of Camrelizumab based cross-line therapy for patients with advanced NSCLC in the real world